stocktitan.net
Phase 2 Trial: Ventyx's VTX958 Shows Strong Endoscopic Response in Crohn's Disease ...
New oral TYK2 inhibitor data show promise on endoscopic healing and inflammatory markers in Crohn’s disease, which is important because oral treatment options are limited. However, the trial missed its main symptom-based endpoint, so the results are encouraging but preliminary.
Adults with Crohn’s disease, patients interested in new oral therapies or clinical trials, gastroenterologists, and IBD researchers.
What To Know
Ventyx presented Phase 2 data for VTX958, an oral TYK2 inhibitor, in moderately-to-severely active Crohn’s disease.
The trial (N=109) did not meet its primary symptomatic endpoint (change in CDAI at Week 12) but showed dose-dependent, statistically notable endoscopic improvements (SES‑CD) and reductions in inflammatory biomarkers (CRP and fecal calprotectin).
Company materials and a conference poster/abstract at ECCO 2025 and an abstract in Journal of Crohn’s and Colitis are cited. The headline findings focus on endoscopic response rather than symptomatic improvement.
Endoscopic response rates were higher with VTX958 225 mg and 300 mg twice daily compared with placebo at Week 12, and biomarker reductions were reported. Safety was described as favorable in the announcement. Full 52‑week data and longer follow-up are still being analyzed and will influence next steps.
How to read this: This is an early-phase (Phase 2) trial reported by the company and presented at a conference; such results are preliminary and meant to guide further development rather than change clinical care now. The trial missed its primary symptomatic endpoint, which tempers the positive endoscopic and biomarker signals.
No treatment recommendations: If you are a patient, discuss any questions about TYK2 inhibitors or trial enrollment with your gastroenterologist or care team; this note is a summary of the company’s announcement, not medical advice.
This is a company press release and conference poster/abstract reporting Phase 2 results. The trial did not meet its primary symptomatic endpoint (CDAI change), and the company notes a high placebo response may have affected that outcome. Full 52‑week data and peer-reviewed publication details will provide more context about durability, safety, and clinical benefit.
The report does not change current treatment guidelines.
